Page 1

Q3-2021 Results HIGHLIGHTS Q3-2021 Sales increased by Ps . 556.0 million ; + 16.2 % year - on - year Q3-2021 EBITDA closed at Ps . 819.0 million ; + 6.5 % year - on - year Ps . 1.76 billion in Cash & Equivalents as of September 30 , 2021 Q3-2021 Net Debt to EBITDA ratio of 1.49x The Company received Good Manufacturing Practices ( GMP ) certification during 3Q - 2021 12th Consecutive Quarter of top - line growth Record EBITDA in absolute terms 1 ) Genomma Lab Internacional Reports Third Quarter 2021 Results Mexico City , October 27 , 2021 - Genomma Lab Internacional , S.A.B. de C.V. ( BMV : LAB B ) ( " Genomma Lab " or " the Company " ) , today announced its results for the third quarter ended September 30 , 2021. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards ( IFRS ) . The following tables provide an abridged Income Statement , in millions of Mexican pesos . The margin for each figure represents its ratio to net sales and the percentage change in the third quarter 2021 as compared with the same period in 2020 : Net Sales Gross Profit Operating Income EBITDA ( 1 ) Net Income Q3 2021 3,983.9 2,454.9 783.5 819.0 393.2 Genomma Lab % Sales 100.0 % 61.6 % 19.7 % 20.6 % 9.9 % Comments from the CEO Q3 2020 3,427.9 2,189.9 731.7 769.4 409.1 EBITDA defined as operating income before depreciation and amortization Internacional % Sales 100.0 % 63.9 % 21.3 % 22.4 % 11.9 % Var . % 16.2 % 12.1 % 7.1 % 6.5 % ( 3.9 % ) Mr. Jorge Luis Brake , Genomma Lab's Chief Executive Officer , commented : " We recently celebrated Genomma's 25 - year anniversary of delivering value to our many important stakeholders . The commemoration was also an opportunity to reflect on our Company's commitment to strong sustainable growth through innovation and disruption . This long - term vision enabled another consecutive quarter of exceptional top - line , operational and profitability results despite the challenging operating environment , driven by an increased market presence with exciting line extensions , new formulations , and product launches during the quarter . Genomma's success in this regard underscores our Company's resilience , and our ability to flexibly adapt to consumers ' needs . However , it's also testament to our operating management team's considerable skill and experience , particularly our strengthened supply chain team , and their ability to maximize our potential by leveraging and expanding our innovation , portfolio and brands ' success throughout new channels and markets . " He added : " The GMP certification we were granted for our solids and semi - solids manufacturing facility during the third quarter was another important milestone in optimizing our supply chain- one of the four pillars of Genomma's growth strategy . Our new fully - operational industrial cluster enables us to improve product quality and our overall value proposition while reducing manufacturing costs and inventory levels , with an improved cash conversion cycle . " www.genommalab.com/inversionistas/ 1